Patient-Derived Xenograft (PDX) Models as Avatars for Patient Response to Therapy
The promise of personalized medicine in cancer will only be met once physicians have both the arsenal of therapeutics they need and a more complete understanding of genomic tumor profiles.
Molecularly Targeted Therapy and Immunotherapy: The Next Frontier in Metastatic Bladder Cancer
A major step toward improved tolerability of cisplatin-based therapy came in the early 2000s with the advent of the modern regimen of gemcitabine and cisplatin.
Genes That Drive Clear-Cell RCC Discovered, Providing Research Clues
A genomic analysis of renal cell carcinoma (RCC) has uncovered new clues about the development, growth, and spread of the cancer.
A Revolution in Classifying Cancer?
A disruptive study challenges our current system in classifying
cancer. Will a new molecular taxonomy of tumors arise and
change our views on patient management?
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.